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It is  well  established  that the propensity of the  influenza virus to cause recurring 
epidemics  and  pandemics  is  due  to  its  extraordinary  antigenic  variability.  Current 
concepts of  the mechanisms underlying these antigenic variations were recently reviewed 
(1,  2).  It  is  thought that  major antigenic  changes  (antigenic  shiR)  may result  from 
recombinations between human and/or animal influenza strains,  whereas minor anti- 
genic changes (antigenic driR) may be due to mutations of the viral genome which affect 
the antigenicity of the viral surface subunits.  In both instances,  the antigenic changes 
are  such  that  the  newly arising  virus strain  can  bypass,  at  least  partially,  the  pre- 
existing antiviral immunity of  the host population. Since only antibodies directed against 
the viral  hemagglutinin  (HA)  ~ are able to neutralize  the  virus and,  consequently, to 
prevent  an  infection,  the  antigenically  modified  HA  is  a  prerequisite  of each  new 
epidemic virus strain.  Antigenic changes also occur in the second viral surface compo- 
nent, the neuraminidase (NA), but these changes seem to be of lesser importance for the 
survival of the virus as a human pathogen. 
The structural correlate of the antigenic variability of the HA is still poorly under- 
stood.  Both approaches that  have  previously been  applied  to  its  analysis  have some 
obvious shortcomings. On the one hand, analysis and comparison of peptide maps of HA 
subunits  requires  relating differences to antigenicity  (3-5) since antigenic variability 
refers only to those structures of the HA that interact with the immune system. On the 
other hand, the immunological approach has been hampered by the fact that sera raised 
in  vivo against  the  purified  HA  or  an  appropriate  hybrid  virus  are  not  necessarily 
monospecific with regard to the individual antigenic determinants of the HA (4,  6-9). 
Yet, the accurate characterization of the antigenicity of the HA, essential to an under- 
standing of antigenic variation,  will  depend  largely on the  availability of antibodies 
monospecific for individual determinants. 
In a  previous report the production in vitro of monoclonal and consequently 
monospecific antiviral  antibodies  was described  (10).  This  study presents  the 
application of these antibodies to an analysis of the antigenic structure of the 
HA of the influenza virus PR8 [A/PR/8/34 (HON1)]. This analysis demonstrates 
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that  the  antigenic  area  of the  HA  of PR8  contains  at  least  eight  (groups of) 
antigenic  determinants.One  of these  determinants  is strain specific, whereas 
the others occur in a cross-reactive form on the HA of one or several A0 and A1 
virus strains. 
Materials and Methods 
Virus.  The influenza virus strains PR8 [A/PR/8/34(HON1)], WSE [A/WSE/33/(HON1)], MEL 
[AlMel./35/(HON1)], BEL  [A/Bel./42/(HON1)],  and  CAM  [A/Cam./46/(HIN1)] were  originally 
obtained in the form of high infectivity stocks from Dr. S. Fazekas de St. Groth, CSIRO, Molecular 
Genetics,  Sydney,  Australia.  The  hybrid  virus  Eq-PR8  [A/equine/Miami/l/63(Heq  2)-A/PR/8/ 
34(N1)]  was kindly provided by Dr. R. Webster, St. Jude Children's Research Hospital, Memphis, 
Tenn.  All viruses were grown in the allantoic cavity of ll-day-old chicken eggs and purified by 
adsorption to and elution from human erythrocytes followed by velocity sedimentation in a linear 
sucrose gradient (11). The HA activity of the virus preparations was determined as described by 
Fazekas de St. Groth and Webster (12). 
Immunization  of Mice.  Young adult male BALB/c mice (Carworth Farms,  Div. of Beckton, 
Dickinson & Co., N. Y., and Flow Laboratories, Inc., Rockville, Md.) were injected intraperitone- 
ally with approximately 1,250 HA units of purified PR8 virus in phosphate-buffered saline. 
Splenic Fragment Cultures.  Procedures for preparing spleen cells from PRS-primed mice for 
the adoptive cell transfer into lethally irradiated syngeneic recipient mice and for preparing the 
splenic fragment cultures were as previously described  (10). The culture fluid from individual 
splenic fragments producing antiviral antibody was harvested at 3- to 4-day intervals between the 
6th and the 30th day after secondary antigenic stimulation in vitro and was pooled before being 
analyzed in the radioimmunoassay  (RIA) for the reactivity of the secreted antibodies. 
RIA.  The preparation  of the viral immunoadsorbents  (IAds) (purified influenza virus cova- 
lently coupled to bromoacetyl-cellulose) and the methodology involved in the quantitation  and 
analysis of small amounts of antiviral antibodies was as described previously (10, 13). 125I-labeled 
rabbit  anti-mouse  F(ab')2  antibody  which detects all mouse immunoglobulin classes was used 
throughout this analysis. 
Measurement of Neutralizing  Activity  of Antibodies.  Virus  neutralization  was  performed 
using the allantois on shell system as described by Fazekas de St.  Groth et al.  (14) with some 
modifications. Briefly, medium 199 with Hanks' salts (Flow Laboratories, Inc.) was used, supple- 
mented with 50/~g/ml of gentamicin (Schering Diagnostics Div., Schering Corp., Port Reading, N. 
J.), 2 ~g/ml of fungizone (E. R. Squibb & Sons, New York), 0.5% (wt/vol) of bovine serum albumin, 
and buffered with either 2.6 ml of 0.336 M HEPES buffer, pH 7.2 (Sigma Chemical Co., St. Louis, 
Mo.) or 1.5 ml 5.6%  (wt/vol) of sodium bicarbonate/100 ml medium. The allantois on shell pieces 
were distributed into the wells of multidish disposo trays (CV-96-TC; Linbro Chemical Co., New 
Haven, Conn.) containing 0.2 ml HEPES-buffered medium per well. One drop (30-40 ~1) of culture 
fluid  from  individual  antibody-producing  splenic  fragments,  followed by  30-40  ~l  of various 
concentrations of virus and 0.2 ml of bicarbonate-buffered medium were added to each well. The 
culture plates were incubated stationary at 35°C in a humidified atmosphere of OJCO2 (93%/7%). 
After 3 days of incubation the culture fluid from each individual bit of shell was analyzed for the 
presence of HA activity as a measure of virus growth. Each titration was performed in duplicate or 
quadruplicate. The neutralizing activity of antibedy-containing culture fluids was compared to the 
virus infectivity titer observed in the presence of an  identical concentration of normal splenic 
fragment culture medium. 
Measurement of the Neuraminidase-Inhibiting  (NI) Activity.  The NI test followed essentially 
the procedure recommended by the W. H. O. International Reference Centers for Influenza (15). 
Briefly, duplicate samples  (75  ~1) of undiluted culture fluids from individual splenic fragments 
that secreted antiviral antibodies were incubated for 2 h with the appropriate dilution of purified 
PR8 virus. Several culture fluids from splenic fragments that did not contain detectable amounts 
of antiviral antibody were included in each assay as controls. The rest of the procedure followed 
the W. H. O. recommendations exactly. A reduction of the absorbancy at 549 nm by more than 50% 
[compared to the mean of the control samples (0.7-1.0)] was regarded as indicating the presence of 
antibodies with NI activity. WALTER  GERHARD  987 
TABLE  I 
Partial Degree of  Interaction  of Monofocal Anti-HA (PR8) Antibodies as Detected in RIA 
and Assignment of Reactivity Pattern 
Culture fluid no. 
Fraction  of  monofocal  anti-HA(PRS)  antibody  binding  to  viral  immu- 
noadsorbent  in RIA* 
PR8  WSE  MEL  BEL 
%  Logs  %  Log2  %  Logs  %  Logs 
7/251  100  0  111  +0.15  <5  -<4.32  100  0 
8/55  100  0  15  -2.74  <2  <-5.54  28  -1.84 
7/161  100  0  73  -0.45  <3  -<5.06  21  -2.25 
Assigned  reactivity 
pattern 
+  +  --  + 
* The binding of the indicated monofocal antibodies to the various IAds is expressed both as 
percentage (%) and a fraction  on a log2  basis  (logs)  of the homologous interaction.  Entries 
represent  averages  of  four  samples  in  the  case of  the  homologous interaction  (PRS)  and  of  three 
samples  in  the  case  of  the  heterologous  interactions.  A difference  of  1.36  in  the  extent  of  binding 
ofa  monofocal  antibody  (on  logs  basis)  is  significant  at  95%  confidence  limit  (Student's  t  test). 
Results 
Determination  of  the  Reactivity  Pattern  (RP)  of  Monofocal  Antibod- 
ies.  Replicate samples (usually 25 ~1) of the pooled culture fluid of individual 
antibody-producing splenic fragments were assayed in the RIA for the extent of 
antibody interaction  with homologous and heterologous IAds.  The amount of 
antibody in 25 ~l of culture fluid (average of four determinations) which bound 
to the homologous IAds (PRS) was taken as the reference value  (100%) of the 
antibody content of the given culture fluid and all heterologous antibody-IAds 
interactions (average of RIA performed in duplicate or triplicate) were expressed 
as a  percentage thereof.  As exemplified in Table I,  heterologous interactions 
ranged  usually from nondetectable to  100% and in some instances more than 
100% of the homologous binding.  The reproducibility  of these partial  binding 
values was assessed by repeated testing of various monofocal antibodies.  The 
average standard deviation of a binding value thus obtained was, on a log2 basis, 
_+0.48. These partial binding patterns were disregarded,  however, for the most 
part of this study.  Instead,  simplified types of RP,  all  (+) or none  (-),  were 
assigned to each antibody (Table I) on the basis of its reactivity in the RIA as 
follows: (a) Given the minimal  amount of antibody used per assay (3 ng)  and 
given the lower limit of antibody detection in the RIA (0.2-0.3 ng), less than 10% 
(in general nondetectable) of the homologous interaction was scored as negative 
reactivity.  (b)  Any  degree  of binding  that  comprised  more  than  10%  of the 
homologous interaction  was scored as positive reactivity even though selected 
monofocal antibodies within each RP could be shown to differ significantly (95% 
confidence limit in Student's t test) from each other with regard to their cross- 
reactivity  (Table  I).  These  RP  were  highly  reproducible;  only in  2 out of 72 
repeat assays did the results indicate a  difference of the RP of two monofocal 
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Determination of the Antibody Specificity.  Monofocal anti-PR8  antibodies 
were assayed in the RIA for their reactivity to the homologous virus, PR8; the 
hybrid virus, Eq-PR8 (both egg-grown); and the partially purified chicken host 
component (ChHC) as previously described (10). Since the standard PR8 virus 
and the parent virus used for the production of the Eq-PR8 hybrid originated 
from the same laboratory it was assumed that these two viruses differ antigeni- 
cally only with respect to their HA, and that antibodies binding to PR8 but not 
to Eq-PR8 and ChHC were therefore directed against a determinant of the HA of 
PR8. To verify the validity of this method, various monofocal antibodies were 
tested in functional assays for their neutralizing or NI activity. 
The  splenic  fragment  culture  fluids  used  in  neutralization  and  NI  tests 
contained at least 5  ng and 3.5 ng of antibody/25  ~l,  respectively (Table II). 
Eight antibodies with anti-NA specificity (determined on the basis of the RIA) 
behaved  in  the  functional  assays  essentially as  expected  (16-18),  i.e.,  they 
inhibited the enzyme activity of PR8 and exhibited only a borderline neutraliz- 
ing activity. All 10 monofocal antibodies with anti-HA specificity, on the other 
hand, neutralized efficiently the homologous virus. However, 4 out of 22 anti- 
HA antibodies also inhibited the NA activity of PR8. There are several possible 
explanations for this unexpected NI activity of the four monofocal antibodies 
which scored as anti-HA antibodies in the RIA: (a) the NA of PR8 may contain a 
determinant not shared by the NA of the hybrid virus Eq-PR8; (b) the culture 
fluids may be biclonal in origin and contain, besides anti-HA antibodies, either 
a  small quantity (<0.25  ng/25  ~1) of anti-NA antibodies of high avidity (and 
thus  of a  high  NI  potency)  or  anti-NA  antibodies  directed against  an  NA 
determinant that  was  altered during preparation  of the viral  IAds  (13);  (c) 
certain anti-HA antibodies may be more efficient in sterically inhibiting the 
viral NA or may express a  minor cross-reactivity with NA when a  polyvalent 
antibody-virus interaction is possible (7, 19). Since these antibodies of question- 
able  specificity would  represent only a  small  fraction  (roughly  12%) of the 
antibodies included in this analysis, they should not interfere with the overall 
relevance of the analysis for determinants of the HA.  In the following it  is 
assumed that all "anti-HA" antibodies (specificity determined by means of the 
RIA) are directed against the HA. 
Table  III  shows  the  various  patterns  of  interactions  of monofocal  anti- 
HA(PR8) antibodies with the homologous and four heterologous viruses. Several 
points  are  evident.  First,  14  of the  16  theoretically possible  cross-reactivity 
patterns  [cross-reactivity patterns  (CRP)  are defined as  RP  exclusive of the 
homologous interaction with PR8]  were realized, though at greatly differing 
frequency, by monofocal antibodies (Table III, first column). The analysis of an 
additional 131 monofocal antibodies obtained by the stimulation in vitro of PR8- 
primed spleen cells by heterologous viruses essentially confirmed the various RP 
as  indicated in Table III.  Thus,  RP no.  15  apparently cannot be realized by 
BALB/c antibodies  or the corresponding precursor B  cells occur at very low 
frequency and RP no. 2 was exhibited only by i  (antibody biclonal in origin?) out 
of 225 monofocal anti-PR8 antibodies tested so far. On the other hand, antibodies 
of RP  nos.  1,  3,  4,  13,  14,  and  especially  16  were frequently observed and 
constituted roughly 80% of the anti-HA(PR8) antibodies. The data thus suggest 
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TABLE  II 
Comparison of Monofocal A ntiviral Antibodies in RIA and Functional Assays 
Reactivity of monofocal anti- 
bodies detected  in RIA* 
No. of  monofocal antibodies  tested  in 
functional  assays 
Assigned anti- 
Neutralization of  Inhibition of NA 
Immunoadsorbent  body specificity  PR8$  activity of PR8§ 
PR8  Eq-PR8  ChHC  +  -  +  - 
+  -  -  Anti-HA  10  0  4  18 
+  +  -  Anti-NA  0  3  5  0 
Randomly selected monofocal antibodies were tested for their specificity in the RLA and in either 
one of the functional assays. 
* The criteria for positive and negative reactivity in the RIA as well as the composition of the viral 
LAds is explained in the text. ChHC, partially purified chicken host component. Neutralization 
and NI were performed as described in the Materials and Methods. 
Neutralization of more than 300 ID,o of PR8  (+); equal or less than 10 ID~o (-). 
§  +, more than 50%  inhibition of NA activity of PRS. 
TASLE  III 
Reactivity of Monofocal Anti-HA (PR8) Antibodies 
Reactivity  pat- 
tern*  Number of 
RP no. 
clones$ 
% Antibody binding  in RIA (average)§ 
P  W  M  B  C  WSE  MEL  BEL  CAM 
1  +  +  +  +  +  5  44  22  78  69 
2  +-  ++  +  0  0  0  0  0 
3  +  +  -  +  +  7  55  <5  60  85 
4  +  +  +  -  +  8  86  56  <4  59 
5  +  +  +  +  -  4  51  79  71  <6 
6  +  -  -  +  +  2  <6  <6  59  33 
7  +  -  +  -  +  3  <5  29  <5  30 
8  +  -  +  +  -  3  <7  71  40  <7 
9  +  +  -  -  +  2  21  <5  <5  84 
I0  ÷  +  -  +  -  1  108  <4  59  <4 
11  +  +  +  1  51  11  <3  <3 
12  +  -  -  -  +  3  <5  <5  <5  27 
13  +  -  -  +  -  6  <4  <4  40  <4 
14  +  -  +  -  -  11  <4  68  <4  <4 
15  +  +  0  0  0  0  0 
16  +  38  <3  <3  <3  <3 
* Definition  of  an RP as  explained in  the Materials and Methods. Viral  LAds:  P, PR8; W, WSE; M, 
MEL; B, BE~; and C, CAM. 
Number of  monofocal antibodies  exhibiting  the indicated  RP. 
§ Geometric mean of  the fraction  of  the various antibodies  binding to the indicated  viral  IAds. 
Expressed as percentage of  the homologous interaction:  PR8, 100%. 
at similar  frequency  (such  as RP  nos. 3  and  14,  or 4, and  13) or cannot  be realized 
at  all  (such  as  RP  nos.  2  and  15). 
Second,  Table  III shows  that,  since  neither  antibodies  reactive  to a  heterolo- 
gous  virus  but  nonreactive  to the  homologous  virus  nor  antibodies  of RP  no.  15 
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populations.  On  the  other  hand,  RP  nos.  1-8  could  theoretically  be  due  to 
various combinations of the aforementioned antibodies (e.g., RP no. 4 could be 
due to a mixture of antibodies of RP nos. 11 and 12). This is unlikely, however, 
for two reasons:  (a) the fraction of polyclonal antibodies is estimated to be less 
than  10%  of the  monofocal  antibodies  included  in  Table  III;  (b)  given  the 
observed frequencies of antibodies of RP nos. 9-16 and assuming that combina- 
tions would occur randomly,  roughly only 5% of the combinations of two such 
antibodies would actually lead to the generation of an RP of nos. 2-8. Thus,  if 
10% of the monofocal antibodies would be polyclonal in origin, the 62 antibodies 
of RP nos. 9-16 would produce less than one biclonal antibody of RP nos. 2-8. 
Third,  it  is evident from the  average  amounts  of the  monofocal  antibodies 
binding to the various viruses that a clear-cut difference exists between detecta- 
ble and nondetectable binding of these antibodies in the RIA.  (The only excep- 
tion, the antibody of RP no. 11, has also been observed in other experiments not 
included in Table III.) The antibodies of each RP generally interacted less with 
the heterologous viruses than with the homologous virus. Heterologous interac- 
tions that exceeded the homologous interaction were observed, however, espe- 
cially with antibodies ofRP nos. 1 and 5. This is demonstrated in Table IV where 
11  monofocal  antibodies  of RP no.  5  are  grouped  according  to the  fractional 
extent of cross-reaction,  in such a  way as to produce subgroups with standard 
deviations  (SD)  that  did  not  significantly  exceed  the  SD  of binding  values 
observed when monofocal antibodies were assayed repeatedly (0.48). The data of 
Table IV further shows that the monofocal antibodies of RP no. 5 (and probably 
of most other RPs defined in this study) are not a homogenous group of antibod- 
ies. Yet, the number of antibodies with slightly different reactivities to the viral 
HA is probably considerably smaller than the number of antibodies included in 
a  given RP. 
Discussion 
The antibodies used in this analysis were produced in vitro  in an  adoptive 
transfer system. Such antibodies have previously been shown to fulfill various 
criteria of monoclonality  (10,  20)  and  roughly 90%  of the antibodies produced 
under the present experimental  conditions are expected, on the basis of these 
arguments, to be monoclonal in origin. They thus represent individual homoge- 
neous populations of antibody-combining sites,  and  hence fulfill the  ultimate 
criterium  of monospecificity.  In  contrast,  the  monospecific  anti-HA  antisera 
applied  in  previous  studies,  though  specific  for  the  given  viral  protein,  are 
composed of a vast array of antibodies with specificities for an unknown number 
of determinants of the viral HA. They delineate, therefore, the overall antigen- 
icity  of the  HA  or  an  undefined  portion  thereof.  Furthermore,  the  present 
finding of many individual anti-HA antibody clones implies that ~ntisera pro- 
duced in vivo, even those induced by cross-stimulation or those cross-absorbed, 
may still contain  heterogeneous antibody populations.  Thus,  any variation  in 
the  relative  concentration  of individual  antibody  populations  composing  an 
antiserum  may  result  in  a  different  apparent  specificity  (9)  and  may  yield 
incorrect assessments of the determinants being analyzed. 
The present study demonstrates that the broad antigenic relationship of viral 
HA of the A0 and A1 subtype can be resolved by means of monoclonal antibodies WALTER  GERHARD 
TABLE  IV 
Heterogeneity  of Antibodies of Same RP (no. 5) with Regard to their 
Partial Degree of Cross-Reaction 
991 
Fraction* (logs)  of  antibody  binding  in RIA (mean ± SD) to immuno- 
adsorbent 
No. of  clones 
WSE  MEL  BEL  CAM 
5  -0.77  ±  0.54  -0.65  ±  0.52  -0,66  ±  0.51  _<4.64 
4  -0.95  ±  0.67  +1.36  ±  0.65  +0.84  ±  0.60  -<3,83 
1  -3.06  +0.62  +0.23  _<3.64 
1  -2.84  -2.32  -2,32  -3,83 
* Relative to homologous (PRS) interaction. 
into  many of its  integral  antigenic  relations.  If the  various  antibody-virus 
interactions observed in the RIA are defined as all  (+)  or none  (-)  types of 
reactions (RP) 14 antigenically different structures of  the five viral HA included 
in this analysis can be distinguished. It seems likely, however, that the number 
of antigenic sites discriminated in the form of the various RP underestimates 
the actual number of HA determinants that can be identified by monoclonal 
anti-PR8  antibodies.  First,  the  monoclonal antibodies  of a  given  RP  rarely 
reacted to the same extent with homologous and heterologous HA as would be 
expected if  they shared an identical determinant. Second, the various antibodies 
within a  given RP were heterogeneous with regard to their extent of cross- 
reaction, suggesting that individual antigenic sites may not represent a single, 
but rather a group of  antigenic determinants. Henceforth, the term determinant 
will be used to designate the antigen structure of the heterologous HA which 
cross-react with the various monoclonal anti-PR8 antibodies of a given RP. 
In addition to delineating a  total of 13  antigenic determinants on the four 
heterologous viruses,  all  anti-PR8  antibodies  included  in  this  analysis also 
reacted with the homologous HA(PR8). Two alternatives must be considered in 
interpreting  this  finding  with  regard  to  the  antigenic  composition  of the 
HA(PRS) itself. (a) The antibodies of each RP could be specific for an individual 
determinant of  the HA(PRS) that occurs in an identical or cross-reactive form on 
one  or  several  of the  heterologous HA;  the  HA(PRS)  would  thus  contain  a 
minimum of 14 distinct antigenic determinants and each of  the heterologous HA 
would contain, probably in addition to determinants not present on the HA of 
PRS,  a  different combination of seven HA(PR8) determinants (Table III).  (b) 
Alternatively, various RP  might merely reflect the heterogeneity of the hu- 
moral immune response to only few determinants of the homologous HA. Thus, 
it would be conceivable that two monoclonal antibodies contain combining sites 
which are identical in the structures that interact with a given determinant of 
the HA(PR8) but differ in those structures that are involved in the discrimina- 
tion of heterologous determinants (21, 22). This type of heterospecificity at the 
level  of individual  combining sites  has  been  observed  in  the  interaction  of 
homogeneous populations of  antibodies with structurally dissimilar haptens (23, 
24). However, since the anti-PR8 antibodies demonstrated the presence of seven 
cross-reactive antigenic determinants on each heterologous HA,  it seems rea- 
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one strain-specific and, analogous to the heterologous HA, seven cross-reactive 
determinants. Presently, it seems difficult either to prove or to exclude whether 
this  latter  mechanism  is  responsible  for  the  generation  of part  of the  RP 
demonstrated in this analysis. The observation, that various pairs of reciprocal 
CRP tended to occur at similar frequency such as RP nos. 4 (PWMBC: +  +  +  - 
+) and 13 (+  -  -  +  -) or not at all such as RPnos. 2 (+  -  +  +  +) and 15 (+  + 
-  -  -) seems, however, to favor the idea that reciprocal CRP may be due to the 
heterogeneity of the antibody response to a single HA(PR8) determinant. 
The recent studies from the laboratories of Schild, Laver,and Webster (4, 6-8) 
have clearly established the fact that the viral HA contains at least two (groups 
oG antigenic determinants, one strain specific and the other common to several 
virus strains. Their evidence was based on the demonstration of partial identity 
in immunoprecipitation tests between different virus strains and monospecific 
anti-HA antisera and on the ability to remove antibodies reactive to  either 
determinant(s) completely and selectively by adsorption of the serum with the 
appropriate virus strain. Furthermore, those studies demonstrated that in the 
course of the antigenic drift, i.e. the gradual change of the antigenicity of the 
HA of successively arising interpandemic virus strains, the strain-specific HA 
determinant(s) underwent major antigenic changes, whereas other (common) 
determinant(s) remained unchanged. 
The present analysis further extends the above mentioned observations with 
regard to the so-called common HA determinant(s).  This latter determinant 
could be dissected by means of the monoclonal anti-PR8 antibodies into several 
(7-13)  distinguishable  determinants.  Each  of these  determinants  (with  the 
possible exception of one) occurred in an antigenically changed form on two of 
several of the virus strains included in the analysis. Thus, the partially shared 
determinants undergo antigenic changes similarly to the strain-specific deter- 
minant(s).  It  is  interesting,  however,  that  the  antigemc variability in  the 
former determinants seems to be  rather unordered and does not reveal  any 
evidence of a relationship between the observed antigenic changes and the year 
when the given virus strain was originally isolated. Thus, the virus CAM (year 
of original isolation, 1945) shared with PR8 (1934) an identical number of cross- 
reactive determinants and interacted in the RIA with roughly the same number 
of anti-PR8  antibodies  as  did  BEL  (1942) or  MEL  (1935). Experiments  are 
currently underway to further delineate this set of partially shared determi- 
nants by means of monoclonal antibodies raised against other A0 virus strains. 
This  set  of partially shared  determinants may represent  a  highly variable 
protein  structure  from which  originate the  major changes  that  lead  to  the 
formation of the various strain-specific determinants. 
The well established broad cross-reactivity of  A0 and A1 HA (2, 7, 8, 21, 25, 26) 
is due to this set of partially shared determinants. Of particular interest is the 
determinant delineated by the antibodies of RP no. 1. This determinant occurs 
in a cross-reactive form on all five virus strains used in this analysis. Since A0 
and A1 virus strains contain the same type of NA two antibodies of RP no.  1 
were also tested in the NI assay; neither of  them inhibited the enzyme activity of 
PR8. It remains, however, to be shown whether this common determinant is also 
present on other A0 and A1 virus strains and especially in view of its potential 
significance in the selection of a vaccine strain or vaccination schedule, whether WALTER  GERHARD  993 
antibodies of  RP no. 1 exhibit also a corresponding cross-reaction  in functional 
assays such as virus neutralization (7). 
In conclusion, the present study demonstrates, firstly,  that the application of 
monoclonal antibodies to the antigenic analysis of  the HA  (and probably of  any 
complex antigen)  is feasible and, secondly, that at the level of monoclonal 
antibodies many  individual HA  determinants can be discriminated.  On the 
other hand, this  study cannot specify  whether these determinants are spatially 
separated or overlapping structures of a single or several antigenic sites  nor 
where on the HA  spike the various determinants are located. However, with 
regard to the solution of these latter questions which  certainly cannot be 
achieved by immunological methods alone, the availability  of  monoclonal anti- 
bodies is likely  to play a crucial  role. 
Summary 
The antigenicity of the hemagglutinins (HA) of five influenza viruses of the 
A0 and A1 subtypes has been analyzed by means of monoclonal antibodies of 
murine origin produced in vitro. Secondary monoclonal anti-HA(PRS) antibod- 
ies were able to differentiate 14 antigenic determinants (or groups of determi- 
nants) on the HA of five influenza virus strains of the A0 and A1  subtypes. 
Taking into account that certain pairs of determinants delineated on heterolo- 
gous HA may reflect the heterogeneity of the humoral immune response to a 
single homologous determinant, the  presence  of at least eight determinants 
(host cell-derived determinants not included) on the homologous HA of PR8 and 
probably on the HA of influenza viruses in general is postulated. 
Three types of HA-determinants of  A0 and A1 influenza virus strains could be 
distinguished: strain-specific, partially shared, and determinant(s) common to 
all  five  virus  strains  tested.  Roughly 40,  55,  and  5%,  respectively,  of the 
secondary anti-PR8 antibodies of BALB/c mice were directed against determi- 
nants belonging to either of the three types. 
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